Clinical Trial Detail

NCT ID NCT02565758
Title ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements no
Sponsors AbbVie
Indications

Advanced Solid Tumor

Therapies

Gemcitabine

Nivolumab

Nab-paclitaxel

ABBV-085

Age Groups: adult

No variant requirements are available.